Larimar Therapeutics Competitors

Larimar Therapeutics (NASDAQ:LRMR) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Insider & Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 59.4% of Dyne Therapeutics shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by insiders. Comparatively, 1.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Dyne Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Larimar Therapeutics and Dyne Therapeutics, as reported by MarketBeat.

Larimar Therapeutics presently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Dyne Therapeutics has a consensus target price of $34.25, indicating a potential upside of 104.48%. Given Dyne Therapeutics' higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Larimar Therapeutics.

Earnings and Valuation

This table compares Larimar Therapeutics and Dyne Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Dyne Therapeutics beats Larimar Therapeutics on 4 of the 6 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

Larimar Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Affimed has a beta of 2.81, meaning that its stock price is 181% more volatile than the S&P 500.

Insider & Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 52.3% of Affimed shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Affimed's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Larimar Therapeutics and Affimed, as reported by MarketBeat.

Larimar Therapeutics presently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Affimed has a consensus target price of $13.50, indicating a potential upside of 38.60%. Given Larimar Therapeutics' higher probable upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Affimed.

Earnings and Valuation

This table compares Larimar Therapeutics and Affimed's revenue, earnings per share (EPS) and valuation.

Affimed has higher revenue and earnings than Larimar Therapeutics.

Summary

Larimar Therapeutics beats Affimed on 7 of the 11 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and Epizyme (NASDAQ:EPZM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

Larimar Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Epizyme has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Earnings and Valuation

This table compares Larimar Therapeutics and Epizyme's revenue, earnings per share (EPS) and valuation.

Larimar Therapeutics has higher earnings, but lower revenue than Epizyme.

Insider & Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 89.8% of Epizyme shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by insiders. Comparatively, 16.3% of Epizyme shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Epizyme's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Larimar Therapeutics and Epizyme, as reported by MarketBeat.

Larimar Therapeutics presently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Epizyme has a consensus target price of $17.00, indicating a potential upside of 103.11%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Epizyme.

Summary

Larimar Therapeutics beats Epizyme on 7 of the 12 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Risk and Volatility

Larimar Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Valuation and Earnings

This table compares Larimar Therapeutics and Amphastar Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Amphastar Pharmaceuticals has higher revenue and earnings than Larimar Therapeutics.

Insider and Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Amphastar Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Larimar Therapeutics and Amphastar Pharmaceuticals, as reported by MarketBeat.com.

Larimar Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Amphastar Pharmaceuticals has a consensus target price of $21.6667, indicating a potential upside of 21.11%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Larimar Therapeutics is more favorable than Amphastar Pharmaceuticals.

Summary

Amphastar Pharmaceuticals beats Larimar Therapeutics on 8 of the 12 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Risk and Volatility

Larimar Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Valuation and Earnings

This table compares Larimar Therapeutics and Collegium Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Collegium Pharmaceutical has higher revenue and earnings than Larimar Therapeutics.

Insider and Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Collegium Pharmaceutical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Larimar Therapeutics and Collegium Pharmaceutical, as reported by MarketBeat.com.

Larimar Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Collegium Pharmaceutical has a consensus target price of $25.00, indicating a potential upside of 7.16%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Larimar Therapeutics is more favorable than Collegium Pharmaceutical.

Summary

Collegium Pharmaceutical beats Larimar Therapeutics on 8 of the 11 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Insider and Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Larimar Therapeutics and ORIC Pharmaceuticals, as reported by MarketBeat.com.

Larimar Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 103.79%. ORIC Pharmaceuticals has a consensus target price of $43.7143, indicating a potential upside of 102.66%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Larimar Therapeutics is more favorable than ORIC Pharmaceuticals.

Valuation and Earnings

This table compares Larimar Therapeutics and ORIC Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Larimar Therapeutics and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Larimar Therapeutics beats ORIC Pharmaceuticals on 4 of the 7 factors compared between the two stocks.